Halozyme Therapeutics, Inc. Announces Successful Annual Meeting and Director Elections

Details

held its Annual Meeting of Stockholders where the stockholders voted on four proposals, including the election of two Class II directors, an advisory vote on executive compensation, a proposal to amend the Certificate of Incorporation, and ratification of Ernst & Young LLP as the independent auditors. All proposals received majority approval, leading to the amendment of the Certificate of Incorporation and re-election of directors. Financial statements and exhibits were also filed, including the Amended and Restated Certificate of Incorporation.

Items reported

Exhibits (1)

About Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.